Bayer ups Ernst Schering Foundation capital 10M euros

23 July 2006

In connection with its acquisition of Schering AG (marketletters passim), the Leverkusen, Germany-based company Bayer AG has increased the capital of the Ernst Schering Foundation 10.0 million ($12.5 million) to 35.0 million euros to put the organization's activities on a sustainable basis. Further, the company museum and parts of Schering's art collection were transferred to the Ernst Schering Foundation.

"The Ernst Schering Foundation has done impressive work. In recognition of this, we have decided to strengthen this organization, which operates internationally from Berlin, for the future," said Werner Wenning, chairman of the board of management of Bayer. "Furthermore, a Foundation of this sort is an excellent fit with our corporate philosophy: social commitment has traditionally been an integral part of Bayer's corporate culture. We currently support more than 300 projects worldwide in the areas of education and research, environmental protection, health and social commitment, sports and cultural activities."

Hubertus Erlen, chairman of the executive board of Schering and deputy chairman of the board of trustees of the Foundation, welcomed this decision, saying: "the additional capital opens up new opportunities for the Foundation to broaden its activities."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight